The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial.
In 85 patients with psoriasis vulgaris the efficacy and tolerance of domoprednate and betamethasone valerate were studied in a double-blind, randomized trial lasting 4 weeks. Complete or satisfactory remission was obtained in 36% in the domoprednate group and in 53% in the betamethasone group. This difference is not statistically significant (p greater than 0.10). 3 patients on each treatment experienced some local irritation. No laboratory abnormalities were found during the study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000031:analogs & derivatives*; D001624:Betamethasone Valerate / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011245:Pregnadienes / Q000008:administration & dosage* / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D011897:Random Allocation
D009824:Ointments; D011245:Pregnadienes; C045340:domoprednate; D001623:Betamethasone; D001624:Betamethasone Valerate